Supraja Reddy Reddy, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1134432479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,667 and has fallen 69.4% since, to $510 in 2025.
Across 410 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Lilly USA, LLC$657
- Boehringer Ingelheim$483
- Novo Nordisk$455
- AstraZeneca$343
- Medtronic$342
- plus $4K from 54 others
What the payments were for
- Food & beverage$7,27598%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,389 in reported general payments places this provider in the 75th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 385 | $619,622 |
| MounjaroTirzepatide | 402 | $617,725 |
| JardianceEmpagliflozin | 381 | $462,201 |
| FarxigaDapagliflozin Propanediol | 333 | $370,303 |
| TrulicityDulaglutide | 122 | $176,414 |
| RybelsusSemaglutide | 41 | $101,221 |
| JanuviaSitagliptin Phosphate | 73 | $82,053 |
| Humalog Kwikpen U-200Insulin Lispro | 67 | $80,190 |
| TradjentaLinagliptin | 86 | $70,355 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $67,047 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $65,965 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $63,634 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $56,049 |
| Humulin R U-500Insulin Regular, Human | 17 | $45,285 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $41,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $657 | $806,867572 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $455 | $733,235470 claims |
| Boehringer IngelheimJardiance, Tradjenta | $483 | $532,556467 claims |
| AstraZenecaFarxiga | $343 | $370,303333 claims |
| MerckJanuvia, Janumet Xr | $28 | $100,78190 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $188 | $67,04743 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $4,382480 claims |
| AbbVieSynthroid | $91 | $2,58134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Sandeep DhindsaSaint Louis$36K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.